Divestment
Hutchmed
Among the first global-focused novel drug discovery companies in China.
HUTCHMED is an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Key Facts
- Sector
Healthcare
- Country
Hong Kong
- Fund
BPEA Private Equity Fund VII
- Entry
2021
- Exit
2025
- Website
- Hutchmed
Do You Want to Know More?
We are eager to explore how we can achieve great things together.
